دورية أكاديمية
أعرض في EDS

Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.

التفاصيل البيبلوغرافية
العنوان: Prognostic value of histopathological DCIS features in a large-scale international interrater reliability study.
المؤلفون: Groen EJ; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Hudecek J; Department of Research IT, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Mulder L; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., van Seijen M; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Almekinders MM; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Alexov S; Department of Pathology, Oncology Hospital, Sofia, Bulgaria., Kovács A; Department of Clinical Pathology, Sahlgrenska University Hospital, Gothenburg, Sweden., Ryska A; The Fingerland Department of Pathology, Charles University Medical Faculty and University Hospital Hradec Kralove, Hradec Kralove, Czech Republic., Varga Z; Institute of Pathology and Molecular Pathology, University Hospital Zurich, Zurich, Switzerland., Andreu Navarro FJ; Atryshealth Co, S.L., Barcelona, Spain., Bianchi S; Division of Pathological Anatomy, Department of Health Sciences, University of Florence, Florence, Italy., Vreuls W; Department of Pathology, Canisius Wilhelmina Hospital, Nijmegen, The Netherlands., Balslev E; Department of Pathology, Herlev University Hospital, Herlev, Denmark., Boot MV; Department of Pathology, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands., Kulka J; 2nd Department of Pathology, Semmelweis University, Budapest, Hungary., Chmielik E; Tumor Pathology Department, Maria Sklodowska-Curie National Research Institute of Oncology, Gliwice Branch, Gliwice, Poland., Barbé E; Department of Pathology, Amsterdam University Medical Center, Location VUmc, Amsterdam, The Netherlands., de Rooij MJ; Symbiant Pathology Expert Centre, Location ZMC, Zaandam, The Netherlands., Vos W; Department of Pathology, Zuyderland Medical Center, Location Sittard-Geleen, Sittard-Geleen, The Netherlands., Farkas A; Department of Pathology, Gävle Hospital, Gävle, Sweden., Leeuwis-Fedorovich NE; Department of Pathology, Deventer Hospital, Deventer, The Netherlands., Regitnig P; Diagnostic and Research Institute of Pathology, Medical University of Graz, Graz, Austria., Westenend PJ; Laboratory for Pathology Dordrecht, Dordrecht, The Netherlands., Kooreman LFS; Department of Pathology and GROW School for Oncology and Developmental Biology, Maastricht University Medical Centre, Maastricht, The Netherlands., Quinn C; Department of Pathology and Laboratory Medicine, St. Vincent's University Hospital, Dublin, Ireland., Floris G; Laboratory of Translational Cell & Tissue Research, Department of Imaging and Pathology, KU Leuven - University of Leuven, Leuven, Belgium.; Department of Pathology, University Hospitals Leuven, Leuven, Belgium., Cserni G; Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary.; Department of Pathology, University of Szeged, Szeged, Hungary., van Diest PJ; Department of Pathology, University Medical Center Utrecht, Utrecht, The Netherlands., Lips EH; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Schaapveld M; Division of Psychosocial Research and Epidemiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands., Wesseling J; Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. j.wesseling@nki.nl.; Department of Molecular Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam, The Netherlands. j.wesseling@nki.nl.
مؤلفون مشاركون: Grand Challenge PRECISION consortium
المصدر: Breast cancer research and treatment [Breast Cancer Res Treat] 2020 Oct; Vol. 183 (3), pp. 759-770. Date of Electronic Publication: 2020 Jul 30.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic Country of Publication: Netherlands NLM ID: 8111104 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-7217 (Electronic) Linking ISSN: 01676806 NLM ISO Abbreviation: Breast Cancer Res Treat Subsets: MEDLINE
أسماء مطبوعة: Publication: Dordrecht : Kluwer Academic
Original Publication: The Hague ; Boston : M. Nijhoff, c1981-
مواضيع طبية MeSH: Breast Neoplasms*/surgery , Carcinoma, Ductal, Breast*/surgery , Carcinoma, Intraductal, Noninfiltrating*/surgery, Female ; Humans ; Mastectomy, Segmental ; Neoplasm Recurrence, Local ; Prognosis ; Reproducibility of Results
مستخلص: Purpose: For optimal management of ductal carcinoma in situ (DCIS), reproducible histopathological assessment is essential to distinguish low-risk from high-risk DCIS. Therefore, we analyzed interrater reliability of histopathological DCIS features and assessed their associations with subsequent ipsilateral invasive breast cancer (iIBC) risk.
Methods: Using a case-cohort design, reliability was assessed in a population-based, nationwide cohort of 2767 women with screen-detected DCIS diagnosed between 1993 and 2004, treated by breast-conserving surgery with/without radiotherapy (BCS ± RT) using Krippendorff's alpha (KA) and Gwet's AC2 (GAC2). Thirty-eight raters scored histopathological DCIS features including grade (2-tiered and 3-tiered), growth pattern, mitotic activity, periductal fibrosis, and lymphocytic infiltrate in 342 women. Using majority opinion-based scores for each feature, their association with subsequent iIBC risk was assessed using Cox regression.
Results: Interrater reliability of grade using various classifications was fair to moderate, and only substantial for grade 1 versus 2 + 3 when using GAC2 (0.78). Reliability for growth pattern (KA 0.44, GAC2 0.78), calcifications (KA 0.49, GAC2 0.70) and necrosis (KA 0.47, GAC2 0.70) was moderate using KA and substantial using GAC2; for (type of) periductal fibrosis and lymphocytic infiltrate fair to moderate estimates were found and for mitotic activity reliability was substantial using GAC2 (0.70). Only in patients treated with BCS-RT, high mitotic activity was associated with a higher iIBC risk in univariable analysis (Hazard Ratio (HR) 2.53, 95% Confidence Interval (95% CI) 1.05-6.11); grade 3 versus 1 + 2 (HR 2.64, 95% CI 1.35-5.14) and a cribriform/solid versus flat epithelial atypia/clinging/(micro)papillary growth pattern (HR 3.70, 95% CI 1.34-10.23) were independently associated with a higher iIBC risk.
Conclusions: Using majority opinion-based scores, DCIS grade, growth pattern, and mitotic activity are associated with iIBC risk in patients treated with BCS-RT, but interrater variability is substantial. Semi-quantitative grading, incorporating and separately evaluating nuclear pleomorphism, growth pattern, and mitotic activity, may improve the reliability and prognostic value of these features.
References: Eur J Cancer. 2015 Nov;51(16):2296-303. (PMID: 26296293)
Breast Cancer Res Treat. 2013 Jun;139(2):453-60. (PMID: 23624751)
Cell Oncol. 2007;29(1):19-24. (PMID: 17429138)
J Natl Cancer Inst Monogr. 2010;2010(41):162-77. (PMID: 20956824)
Nat Rev Clin Oncol. 2019 Nov;16(11):703-715. (PMID: 31399699)
Mod Pathol. 2020 Mar;33(3):354-366. (PMID: 31534203)
J Natl Cancer Inst. 2010 May 5;102(9):627-37. (PMID: 20427430)
Histopathology. 1991 Nov;19(5):403-10. (PMID: 1757079)
Neuroendocrinology. 2014;100(4):288-92. (PMID: 25342217)
Histopathology. 2018 Dec;73(6):923-932. (PMID: 30168167)
Hum Pathol. 1998 Oct;29(10):1056-62. (PMID: 9781641)
J Clin Epidemiol. 1999 Dec;52(12):1165-72. (PMID: 10580779)
Br J Cancer. 2012 Jan 17;106(2):383-8. (PMID: 22251968)
Br J Math Stat Psychol. 2008 May;61(Pt 1):29-48. (PMID: 18482474)
Clin Cancer Res. 2018 Aug 1;24(15):3593-3601. (PMID: 29685879)
Pathol Oncol Res. 2020 Apr;26(2):665-671. (PMID: 31776839)
J Natl Cancer Inst. 2010 Feb 3;102(3):170-8. (PMID: 20071685)
Int J Cancer. 2015 Aug 15;137(4):921-9. (PMID: 25612892)
Br J Cancer. 2010 Jun 29;103(1):94-100. (PMID: 20517310)
Breast Cancer Res Treat. 2016 Oct;159(3):553-63. (PMID: 27624164)
Surg Clin North Am. 1990 Aug;70(4):853-71. (PMID: 2164715)
J Cancer. 2011 May 01;2:232-61. (PMID: 21552384)
BMJ Open. 2019 Mar 12;9(3):e026797. (PMID: 30862637)
Breast Cancer Res Treat. 2006 May;97(2):135-44. (PMID: 16319971)
J Clin Pathol. 1998 Jun;51(6):450-4. (PMID: 9771444)
Pathol Res Pract. 2010 Oct 15;206(10):705-11. (PMID: 20663616)
Hum Pathol. 1997 Aug;28(8):967-73. (PMID: 9269834)
Breast Cancer Res. 2016 May 10;18(1):47. (PMID: 27160733)
Mod Pathol. 1994 Feb;7(2):257-62. (PMID: 7911998)
Eur J Cancer. 2015 Aug;51(12):1497-510. (PMID: 26025767)
JAMA. 2015 Mar 17;313(11):1122-32. (PMID: 25781441)
JAMA Intern Med. 2015 Sep;175(9):1483-9. (PMID: 26147578)
Breast Cancer Res. 2019 Jul 29;21(1):83. (PMID: 31358020)
Eur J Cancer. 2000 Sep;36(14):1769-72. (PMID: 10974624)
Breast Cancer Res Treat. 2019 Apr;174(2):479-488. (PMID: 30539380)
Br J Cancer. 1957 Sep;11(3):359-77. (PMID: 13499785)
Eur J Cancer. 2003 Oct;39(15):2187-91. (PMID: 14522377)
Am J Surg Pathol. 2000 May;24(5):651-9. (PMID: 10800983)
Lancet. 1995 May 6;345(8958):1154-7. (PMID: 7723550)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
Int J Nurs Stud. 2011 Jun;48(6):661-71. (PMID: 21514934)
J Natl Cancer Inst. 2019 Sep 1;111(9):952-960. (PMID: 30759222)
Ann Clin Lab Sci. 2011 Spring;41(2):122-30. (PMID: 21844569)
Lab Invest. 2019 Nov;99(11):1596-1606. (PMID: 31222166)
J Clin Oncol. 2013 Nov 10;31(32):4054-9. (PMID: 24043739)
Semin Diagn Pathol. 1994 Aug;11(3):167-80. (PMID: 7831528)
Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):835-845. (PMID: 31023696)
Diagn Pathol. 2015 Jul 10;10:93. (PMID: 26159429)
معلومات مُعتمدة: NKI2014-7167 KWF Kankerbestrijding; C38317/A24043 Cancer Research UK and KWF Kankerbestrijding in a joint grant
فهرسة مساهمة: Keywords: Ductal carcinoma in situ; Interrater reliability; Invasive breast cancer; Risk stratification
تواريخ الأحداث: Date Created: 20200801 Date Completed: 20210623 Latest Revision: 20240801
رمز التحديث: 20240801
مُعرف محوري في PubMed: PMC7497690
DOI: 10.1007/s10549-020-05816-x
PMID: 32734520
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-7217
DOI:10.1007/s10549-020-05816-x